Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
Taysha Gene Therapies (Nasdaq: TSHA) will report third quarter 2025 financial results for the period ended September 30, 2025, and will host a corporate update conference call and webcast on Tuesday, November 4, 2025 at 8:30 AM ET.
The event includes a toll-free dial-in, international number, and a webcast at https://ir.tayshagtx.com/news-events/events-presentations. Conference ID is TAYSHA. The call time in Central Time is 7:30 AM CT.
Taysha Gene Therapies (Nasdaq: TSHA) riferirà i risultati finanziari del terzo trimestre 2025 per il periodo terminato il 30 settembre 2025, e terrà una conferenza di aggiornamento aziendale e una webcast il martedì 4 novembre 2025 alle 8:30 AM ET.
L'evento include una chiamata senza costi, numero internazionale e una webcast su https://ir.tayshagtx.com/news-events/events-presentations. l'ID conferenza è TAYSHA. L'orario della chiamata nel fuso orario centrale è 7:30 AM CT.
Taysha Gene Therapies (Nasdaq: TSHA) informará los resultados financieros del tercer trimestre de 2025 para el período que terminó el 30 de septiembre de 2025, y organizará una conferencia de actualización corporativa y una webcast el martes 4 de noviembre de 2025 a las 8:30 a. m. hora del Este.
El evento incluye una marcación gratuita, número internacional y una webcast en https://ir.tayshagtx.com/news-events/events-presentations. El ID de la conferencia es TAYSHA. La hora de la llamada en la hora Central es 7:30 a. m. CT.
테샤 게노 테라피스(Taysha Gene Therapies) (나스닥: TSHA)는 2025년 3분기 재무 실적을 2025년 9월 30일 종료 기간에 대해 발표하고, 2025년 11월 4일 화요일 오전 8:30 AM ET에 기업 업데이트 컨퍼런스콜 및 웨비나를 개최합니다.
이 이벤트에는 무료 다이얼인, 국제 번호, 그리고 https://ir.tayshagtx.com/news-events/events-presentations의 웨비나가 포함됩니다. 회의 ID는 TAYSHA입니다. 중부 시간대의 전화 시간은 7:30 AM CT입니다.
Taysha Gene Therapies (Nasdaq : TSHA) publiera les résultats financiers du troisième trimestre 2025 pour la période se terminant le 30 septembre 2025, et animera une conférence téléphonique de mise à jour de l'entreprise et une webdiffusion le mardi 4 novembre 2025 à 8h30 ET.
L'événement comprend un numéro d'appel gratuit, un numéro international et une webdiffusion à https://ir.tayshagtx.com/news-events/events-presentations. L'identifiant de la conférence est TAYSHA. L'heure d'appel dans le fuseau horaire du Centre est 7h30 CT.
Taysha Gene Therapies (Nasdaq: TSHA) wird die Finanzergebnisse des dritten Quartals 2025 für den Zeitraum bis zum 30. September 2025 bekannt geben und am Dienstag, den 4. November 2025, um 8:30 Uhr ET eine Unternehmensupdate-Konferenzschaltung und Webcast veranstalten.
Die Veranstaltung umfasst eine gebührenfreie Telefonleitung, eine internationale Nummer und einen Webcast unter https://ir.tayshagtx.com/news-events/events-presentations. Die Konferenz-ID lautet TAYSHA. Die Anrufzeit in der Central Time ist 7:30 Uhr CT.
ستعلن Taysha Gene Therapies (ناسداك: TSHA) عن نتائجها المالية للربع الثالث من عام 2025 للفترة المنتهية في 30 سبتمبر 2025، وستعقد مؤتمر اتصال وتحديث شركي وبثًا عبر الويب في الثلاثاء 4 نوفمبر 2025 الساعة 8:30 صباحًا بتوقيت شرق الولايات المتحدة.
يتضمن الحدث رقم اتصال مجاني، رقم دولي وبثًا عبر الويب على https://ir.tayshagtx.com/news-events/events-presentations. معرف المؤتمر هو TAYSHA. الوقت في توقيت الوسط الأمريكي هو 7:30 صباحًا CT.
Taysha Gene Therapies（纳斯达克：TSHA）将公布截至2025年9月30日的2025年第三季度财务业绩，并于2025年11月4日星期二美国东部时间上午8:30举行企业更新电话会议及网络直播。
该活动包括免费的拨入电话、国际号码，以及在https://ir.tayshagtx.com/news-events/events-presentations的网络直播。会议ID为TAYSHA。中央时区的呼叫时间为上午7:30 CT。
- None.
- None.
DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2025, and host a corporate update conference call and webcast on Tuesday, November 4, 2025, at 8:30 AM Eastern Time.
Conference Call Details
Tuesday, November 4, at 8:30 AM Eastern Time / 7:30 AM Central Time
Toll Free: 800-245-3047
International: 203-518-9765
Conference ID: TAYSHA
Webcast: https://ir.tayshagtx.com/news-events/events-presentations
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
carolyn.hawley@inizioevoke.com
FAQ
When will Taysha (TSHA) release its Q3 2025 financial results?
What time is the Taysha (TSHA) conference call and webcast on November 4, 2025?
How can I join the Taysha (TSHA) November 4, 2025 webcast?
What dial-in numbers are provided for the Taysha (TSHA) investor call on November 4, 2025?
Will Taysha (TSHA) discuss clinical updates during the November 4, 2025 call?
Where can investors find the Taysha (TSHA) replay after the November 4, 2025 call?
